We narrowed to 5,618 results for: cre encoding plasmid
-
Plasmid#214867PurposeExpression of SYFP2 in striatal medium spiny neurons in a Cre dependent manner; useful for intersectional labelingDepositorInsertSYFP2
UseAAVAvailable SinceJuly 15, 2024AvailabilityAcademic Institutions and Nonprofits only -
AiP11763: pAAV-hEF1a-DIO-ChR2(CRC)-EYFP-WPRE-HGHpA (Alias: CN1763)
Plasmid#236602PurposeA vector for Cre dependent expression of ChR2(CRC)-EYFP; CRC variant contains mutations L132C, H134R, and T159C in ChR2DepositorInsertChR2(CRC)-EYFP
UseAAVAvailable SinceMay 14, 2025AvailabilityAcademic Institutions and Nonprofits only -
AiP15357 - pAAV-AiE0441h_3xC2-minBG-DIO-CoChR-EGFP-WPRE3-BGHpA (Alias: CN5357)
Plasmid#224197PurposeAiE0441h_3xC2 is an enhancer sequence, designed to drive Cre dependent AAV-mediated transgene expression in striatal MSNsDepositorInsertCoChR-EGFP
UseAAVAvailable SinceSept. 27, 2024AvailabilityAcademic Institutions and Nonprofits only -
AiP15355 - pAAV-AiE0784m-minBG-DIO-SYFP2-WPRE3-BGHpA (Alias: CN5355)
Plasmid#224195PurposeAiE0784m is an enhancer sequence, designed to drive Cre dependent AAV-mediated transgene expression in striatal MSNsDepositorInsertSYFP2
UseAAVAvailable SinceSept. 26, 2024AvailabilityAcademic Institutions and Nonprofits only -
AiP15356 - pAAV-AiE0784m-minBG-DIO-CoChR-EGFP-WPRE3-BGHpA (Alias: CN5356)
Plasmid#224196PurposeAiE0784m is an enhancer sequence, designed to drive Cre dependent AAV-mediated transgene expression in striatal MSNsDepositorInsertCoChR-EGFP
UseAAVAvailable SinceSept. 25, 2024AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-double floxed-mCherry-WPRE-HGHpA (AAV9)
Viral Prep#20299-AAV9PurposeReady-to-use AAV9 particles produced from pAAV-EF1a-double floxed-mCherry-WPRE-HGHpA (#20299). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-mCherry-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent mCherry expression. These AAV preparations are suitable purity for injection into animals.DepositorTagsmCherry (Cre-dependent)Available SinceSept. 22, 2025AvailabilityAcademic Institutions and Nonprofits only -
pAAV-double floxed-eNpHR-EYFP-WPRE-pA (AAV9)
Viral Prep#20949-AAV9PurposeReady-to-use AAV9 particles produced from pAAV-double floxed-eNpHR-EYFP-WPRE-pA (#20949). In addition to the viral particles, you will also receive purified pAAV-double floxed-eNpHR-EYFP-WPRE-pA plasmid DNA. EF1a-driven, cre-dependent eNpHR EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsEYFP (Cre-dependent)Available SinceJuly 12, 2018AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (AAV9)
Viral Prep#20298-AAV9PurposeReady-to-use AAV9 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsEYFP (Cre-dependent)Available SinceMarch 30, 2018AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV1)
Viral Prep#20297-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsmCherry (Cre-dependent)Available SinceFeb. 15, 2018AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (AAV5)
Viral Prep#20298-AAV5PurposeReady-to-use AAV5 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsEYFP (Cre-dependent)Available SinceFeb. 15, 2018AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV9)
Viral Prep#20297-AAV9PurposeReady-to-use AAV9 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsmCherry (Cre-dependent)Available SinceMarch 15, 2018AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV5)
Viral Prep#20297-AAV5PurposeReady-to-use AAV5 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsmCherry (Cre-dependent)Available SinceFeb. 15, 2018AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (AAV1)
Viral Prep#20298-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsEYFP (Cre-dependent)Available SinceOct. 12, 2017AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV8)
Viral Prep#20297-AAV8PurposeReady-to-use AAV8 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsmCherry (Cre-dependent)Available SinceDec. 18, 2017AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV Retrograde)
Viral Prep#20297-AAVrgPurposeReady-to-use AAV Retrograde particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsmCherry (Cre-dependent)Available SinceAug. 22, 2017AvailabilityAcademic Institutions and Nonprofits only -
pAAV-FLEX-tdTomato (AAV9)
Viral Prep#28306-AAV9PurposeReady-to-use AAV9 particles produced from pAAV-FLEX-tdTomato (#28306). In addition to the viral particles, you will also receive purified pAAV-FLEX-tdTomato plasmid DNA. CAG-driven, Cre-dependent tdTomato expression control. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagstdTomato (Cre-dependent)Available SinceNov. 30, 2018AvailabilityAcademic Institutions and Nonprofits only -
pAAV-FLEX-tdTomato (AAV1)
Viral Prep#28306-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-FLEX-tdTomato (#28306). In addition to the viral particles, you will also receive purified pAAV-FLEX-tdTomato plasmid DNA. CAG-driven, Cre-dependent tdTomato expression control. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagstdTomato (Cre-dependent)Available SinceFeb. 27, 2019AvailabilityAcademic Institutions and Nonprofits only -
pAAV-FLEX-tdTomato (AAV5)
Viral Prep#28306-AAV5PurposeReady-to-use AAV5 particles produced from pAAV-FLEX-tdTomato (#28306). In addition to the viral particles, you will also receive purified pAAV-FLEX-tdTomato plasmid DNA. CAG-driven, Cre-dependent tdTomato expression control. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagstdTomato (Cre-dependent)Available SinceAug. 4, 2021AvailabilityAcademic Institutions and Nonprofits only -
pAAV-FLEX-tdTomato (AAV8)
Viral Prep#28306-AAV8PurposeReady-to-use AAV8 particles produced from pAAV-FLEX-tdTomato (#28306). In addition to the viral particles, you will also receive purified pAAV-FLEX-tdTomato plasmid DNA. CAG-driven, Cre-dependent tdTomato expression control. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagstdTomato (Cre-dependent)Available SinceOct. 18, 2021AvailabilityAcademic Institutions and Nonprofits only -
pAAV-FLEX-tdTomato (AAV2)
Viral Prep#28306-AAV2PurposeReady-to-use AAV2 particles produced from pAAV-FLEX-tdTomato (#28306). In addition to the viral particles, you will also receive purified pAAV-FLEX-tdTomato plasmid DNA. CAG-driven, Cre-dependent tdTomato expression control. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagstdTomato (Cre-dependent)Available SinceAug. 4, 2021AvailabilityAcademic Institutions and Nonprofits only